NAC (N-Acetyl-Cysteine)

NAC (N-Acetyl-Cysteine) is a stable, orally bioavailable form of cysteine , the rate-limiting amino acid precursor to glutathione (GSH), the body’s master antioxidant. It has one of the longest clinical track records of any supplement, with FDA-approved uses for acetaminophen overdose treatment and mucolytic therapy in cystic fibrosis and COPD. These validated medical applications underpin its broader reputation for antioxidant support, liver protection, and respiratory health.

Glutathione and Antioxidant Support {#glutathione-support}

Glutathione is a tripeptide antioxidant synthesized in virtually every cell. It neutralizes reactive oxygen species, recycles other antioxidants, and supports mitochondrial function. Intracellular GSH levels decline with age, chronic illness, and metabolic stress , a pattern associated with increased oxidative damage and accelerated biological aging.

NAC supplementation raises intracellular glutathione by supplying cysteine, the limiting substrate in GSH synthesis. A 2023 meta-analysis confirmed that NAC significantly increases Total Antioxidant Capacity (TAC) and GSH levels; effects were stronger at doses above 600 mg/day sustained for more than four weeks.

The GlyNAC combination (glycine plus NAC) has attracted attention in the aging and longevity field. A 2022 Frontiers in Aging RCT in healthy older adults found that 24 weeks of GlyNAC supplementation corrected glutathione deficiency, reduced oxidative stress, mitochondrial dysfunction, and systemic inflammation, and improved grip strength, gait speed, cognition, and body composition. This is among the more compelling recent RCTs in the space, though replication in larger trials is still needed.

Exercise Recovery {#exercise-recovery}

A 2024 meta-analysis (PMC11617117) synthesizing NAC trials in exercising adults found that supplementation significantly reduced muscle soreness, blood lactate, IL-6, and TBARS (a lipid peroxidation marker) following exercise, while elevating glutathione. These findings are mechanistically consistent: high-intensity exercise transiently depletes GSH and raises oxidative and inflammatory markers, and NAC buffers that response by maintaining cysteine availability for GSH resynthesis.

The practical implication is modestly faster recovery between sessions , most relevant for athletes training at high frequency or volume, or for individuals with blunted antioxidant capacity.

Respiratory Health {#respiratory-health}

NAC’s mucolytic action is pharmacologically distinct from its antioxidant role. It breaks disulfide bonds in mucus glycoproteins, directly reducing viscosity and making secretions easier to clear. This mechanism underpins its clinical use in cystic fibrosis, COPD exacerbations, and bronchitis. In these conditions, NAC is used at higher doses (600 mg two to three times daily) and is among the better-validated respiratory interventions in pulmonary medicine.

For otherwise healthy individuals, benefits are more modest and context-dependent , most relevant during respiratory illness or in those with chronic mucus overproduction. NAC also supports glutathione levels in lung epithelium, providing a secondary layer of oxidative protection in airway tissue.

Dosing and Safety

Common supplementation doses range from 600 mg to 1,800 mg per day, typically split into two or three doses with food. The 600 mg/day range reflects most antioxidant-focused trials; mucolytic and clinical applications often use 1,200–1,800 mg/day. Most healthy adults tolerate NAC well. The most commonly reported side effect is mild nausea, particularly at higher doses or on an empty stomach. NAC is generally contraindicated in active asthma without medical supervision, as inhalation forms can trigger bronchospasm , though oral supplementation at typical doses is considered safe. Long-term use above 1,800 mg/day has not been extensively studied in healthy populations.